ABSTRACT: Diabetes develops when the insulin needs of peripheral cells exceed the availability or action of the hormone. This situation results from the death of most beta-cells in type 1 diabetes, and from an inability of the beta-cell mass to adapt to increasing insulin needs in type 2 and gestational diabetes. We analyzed several lines of transgenic mice and showed that connexins (Cxs), the transmembrane proteins that form gap junctions, are implicated in the modulation of the beta-cell mass. Specifically, we found that the native Cx36 does not alter islet size or insulin content, whereas the Cx43 isoform increases both parameters, and Cx32 has a similar effect only when combined with GH. These findings open interesting perspectives for the in vitro and in vivo regulation of the beta-cell mass. and/or abnormal sensitivity of peripheral cells to the hormone (1). Type 1 diabetes results from a massive autoimmune destruction of the insulin-producing pancreatic betacells (2). Type 2 diabetes results from a combination of increased insulin resistance of peripheral cells and failure of the beta-cell mass to adapt to the increased needs of insulin (3). Increased needs of insulin are also seen during pregnancy and result in gestational diabetes when beta-cells fail to adequately increase their secretion or mass. In view of the high prevalence of diabetes worldwide, and of the economic burden of current treatments, strategies aimed at increasing the betacell mass could represent a valuable alternative to current approaches. Increasing the beta-cell mass could help to overcome the peripheral resistance to insulin observed in type 2 and gestational diabetes and to improve the effect of cell replacement therapies. Indeed, islet transplantation can normalize blood glucose levels and may prevent the devastating complications of diabetes. However, beta-cells from cadaver pancreases are in such short supply that transplants can be provided only to a limited number of patients, especially because multiple donors are usually necessary to achieve insulin independence of one recipient. The in vitro expansion of isolated islets/islet cells could markedly improve this therapeutic option.
D iabetes results from insufficient secretion of insulin
and/or abnormal sensitivity of peripheral cells to the hormone (1) . Type 1 diabetes results from a massive autoimmune destruction of the insulin-producing pancreatic betacells (2) . Type 2 diabetes results from a combination of increased insulin resistance of peripheral cells and failure of the beta-cell mass to adapt to the increased needs of insulin (3) . Increased needs of insulin are also seen during pregnancy and result in gestational diabetes when beta-cells fail to adequately increase their secretion or mass. In view of the high prevalence of diabetes worldwide, and of the economic burden of current treatments, strategies aimed at increasing the betacell mass could represent a valuable alternative to current approaches. Increasing the beta-cell mass could help to overcome the peripheral resistance to insulin observed in type 2 and gestational diabetes and to improve the effect of cell replacement therapies. Indeed, islet transplantation can normalize blood glucose levels and may prevent the devastating complications of diabetes. However, beta-cells from cadaver pancreases are in such short supply that transplants can be provided only to a limited number of patients, especially because multiple donors are usually necessary to achieve insulin independence of one recipient. The in vitro expansion of isolated islets/islet cells could markedly improve this therapeutic option.
The beta-cell mass adapts to the changing needs of the body throughout life. Thus, the beta-cell population grows postnatally, at least until adolescence (4 -6) . Thereafter, the increase in beta-cell mass continues to an advanced age and is linearly correlated with body weight (7) . However, when a critical threshold is reached, insulin secretion can no longer meet the needs of the body, leading to glucose intolerance or diabetes. Obesity and pregnancy increase the insulin needs and failure to sufficiently increase the beta-cell mass results in type 2 diabetes and gestational diabetes, respectively. Several factors are implicated in the regulation of the beta-cell mass in rodents (8) , including glucose (9 -11), insulin, IGF-I and -II (12) (13) (14) (15) (16) , hepatocyte growth factor (HGF) (17) , PTH-related protein (PTHrP) (18) , GH, prolactin (PRL), placental lactogen (PL) (19) , and glucagon-like peptide-1 (GLP-1) (20 -22) . However, the effect of each of these factors is quantitatively modest and may not necessarily occur in humans (23, 24) . Analysis of the pregnancy situation indicates that other factors are influential in the regulation of beta-cell mass, including possibly the beta-to-beta cell communications that are mediated by connexins (Cxs) (24) . These proteins, which form the gap junction domains of cell membranes (25) (26) (27) , may be key in this process because they have been shown to affect cell proliferation and survival in different cell types (28) . Cxs form a multigene family of 21 members in the human genome (27) . Cx36 is the only Cx isoform expressed in pancreatic beta-cells (29) . Here, we have investigated the effect of various Cx isoforms on the beta-cell mass and the size of pancreatic islets, using a series of existing (30 -31) and newly created transgenic mice, which either overexpressed the native Cx36, were null for this protein, or expressed it in combination with other Cx isoforms, in the presence or absence of human GH (hGH).
was determined by PCR amplification of tail DNA (30 -33) . Three-to six-mo-old mice backcrossed with C57Bl/6 controls (F3-F5 generations) were used in all experiments, which were conducted as per the regulations of the veterinarian office of the State of Geneva (authorization No. 1034/3552/1, April 8, 2010).
Pancreas and islet sampling. Because circadian cycles may influence insulin expression, pancreases of all mice were consistently collected in the morning, for immunostaining, insulin extraction, and islet isolation. Islets of Langerhans were isolated for extraction of total proteins, as previously reported (29 -31) .
Measurement of insulin content. The pancreatic insulin was extracted and measured by RIA as previously reported (34) . Values were normalized to the weight of the whole organ.
Measurement of islet surface. The size of pancreatic islets was measured on pancreatic sections immunostained for insulin, as previously reported (30) . At least 100 islet sections were measured per animal, on pancreatic sections cut throughout the pancreas at intervals of 250 m, in order not to measure the same islet twice (35) . Three to four animals were evaluated for each genotype. Pictures were taken at a 400ϫ magnification. Areas of islet profiles were measured using a graphic tablet and the Quantimet 500 software by Leica (Leica Microsystems, Heerbrugg, Switzerland) or digitized using a MIRAX MIDI slide scanner (Zeiss, Oberkochen, Germany) and analyzed using the MIRAX Viewer software.
Cx expression. The expression of Cx32, Cx36, and Cx43 within the islets of Langerhans was assessed by immunofluorescence staining of pancreas sections and by immunoblotting (Westerns) of total protein extracted from isolated islets, using specific antibodies, as reported in previous publications (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) 33) .
Statistical analysis. Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS 11.0.4, SPSS inc., Chicago). Briefly, the distribution of the data were analyzed by drawing a histogram of the values. For symmetrical distributions (insulin content), average data were expressed as mean Ϯ SEM. For asymmetrical distributions (islet size), average data were expressed as medians. Differences between means were assessed by t test. Differences between medians were assessed by nonparametric tests for independent samples (median test, Mann-Whitney U, and KolmogorovSmirnov Z tests). Differences were considered significant when p Ͻ 0.05.
RESULTS

Animal characteristics.
Cx expression of beta-cells was checked in the RIP-Cx transgenic mice by both immunofluorescence staining of pancreas sections and immunoblotting of total proteins extracted from isolated islets (Fig. 1) . As expected, all control mice (Ϫ/Ϫ genotype) of the three RIP-Cx lines expressed limited levels of the native Cx36 but no detectable Cx32 or Cx43 ( Fig. 1 and Table 1 ). The levels of Cx36 were significantly increased in the islets of RIP-Cx36 ϩ/ϩ mice but not in those of either RIP-Cx32 ϩ/ϩ or RIP-Cx43 ϩ/ϩ animals ( Fig. 1 and Table 1 ). Cx32 was only induced in the islets of RIP-Cx32 ϩ/ϩ mice, whereas Cx43 was only induced in the islets of RIP-Cx43 ϩ/ϩ animals ( Fig. 1 and Table 1 ). We previously reported on the presence of Cx36 in the islets of WT and heterozygous KO-Cx36 mice and its loss in the islets of KO-Cx36 Ϫ/Ϫ littermates (31, 33) .
The KO-Cx36, RIP-Cx36, and RIP-Cx43 transgenic mice had normal levels of plasma insulin and glucose and a normal tolerance to a glucose test (Refs. 31,33 and data not shown). In contrast, the RIP-Cx32 mice had higher basal insulin levels and lower basal circulating glucose than controls and were intolerant to the sugar (30) .
Loss of Cx36 does not affect beta-cell mass. KO-Cx36 mice, which showed a partial (ϩ/Ϫ animals) or complete loss of Cx36 (Ϫ/Ϫ null mice; Fig. 1 and Table 1 ; Refs.31,33) showed a median islet size and pancreatic insulin content similar to those evaluated in their control (ϩ/ϩ) littermates (Fig. 2) . Thus, loss of Cx36 levels did not alter beta-cell mass.
Overexpression of Cx36 does not affect beta-cell mass. RIP-Cx36 mice, which overexpressed Cx36 specifically in beta-cells ( Fig. 1 and Table 1 ), showed an islet size and pancreas insulin content similar to those of their control littermates (Fig. 3) . Thus, increased levels of Cx36 did not alter beta-cell mass.
The beta-cell-specific expression of ectopic Cxs increases the beta-cell mass. RIP-Cx32 mice featured significantly larger islets and a higher insulin content than their control littermates (Fig. 4) . These mice expressed Cx32 and hGH on top of the native Cx36 (Table 1 and Figs. 1 and 5G ) Thus, when expressed with hGH, Cx32 increases islet size and beta-cell mass.
To determine whether this effect was because of Cx32, hGH, or to the combination of the two proteins, we similarly investigated RIP-hGH mice, which express high levels of hGH in beta-cells (Fig. 5F and Table 1 ). These transgenic mice featured an average islet size increased 2-fold compared with controls (Fig. 6A) . However, total pancreatic insulin content was similar in the transgenic mice and their control littermates (Fig. 6B) . Thus, hGH increases islet size but not the total mass of beta-cells.
We similarly studied RIP-Cx43 mice in which beta-cells express Cx43 on top of the native Cx36 but no hGH (Table 1 and Figs. 1 and 5E and G) . We found that these transgenic mice had larger islets than controls (Fig. 7A) . In the homozygous (ϩ/ϩ), but not the heterozygous (ϩ/Ϫ) littermates, this change was paralleled by an increase in total insulin content (Fig. 7B) . Thus, overexpression of Cx43 increases islet size and beta cell mass in the absence of hGH. 
Symbols in columns provide an evaluation of the relative levels of Cx36, Cx32, Cx43, and hGH in beta-cells, as determined by immunolabeling of sections and/or islet membranes. Bold symbols outline native levels of Cx36. Ϫ not detectable; ϩ to ϩϩϩϩ increasing levels. All KO (Cx36) and transgenic lines (RIP-Cx36, RIP-Cx32, RIP-Cx43, RIP-hGH) were backcrossed with C57Bl6 mice. The mice that served as controls for the different lines (Cx36 ϩ/ϩ, RIP-Cx36 Ϫ/Ϫ, RIP-Cx43 Ϫ/Ϫ, RIP-Cx32 Ϫ/Ϫ, RIPhGH Ϫ/Ϫ) featured native levels of Cx36, like WT C57Bl6 controls.
DISCUSSION
By comparing mice expressing different Cx patterns, we have found that Cx36 has no effect on islet size and beta-cell mass, that Cx32 in association with hGH increases these two parameters, and that Cx43 has the same effect also in the absence of the latter hormone. The data indicate for the first time that some Cx species are implicated in the adaptation of pancreatic beta-cells. The finding is noteworthy, inasmuch as modest increases in beta-cell mass have now been documented, at least in rodents, under a variety of experimental conditions of partial pancreas and/or islet cell ablation (8, 24, 36) . However, no physiological condition has yet been shown to induce a sizable increase of beta-cell mass, with the notable exception of pregnancy (23, 24, 37) . Our findings indicate that Cxs may be central to the regulation of beta-cell life in nonpregnant, normoglycemic animals. Strikingly, significant changes in the direct communications that beta-cells establish via Cx channels have also been reported in rodent pregnancy (37) , even though the Cx species involved was not investigated (24) .
In keeping with the different permeability and regulatory properties of the channels made by different Cx species (28,35,38 -40) , we have found that specific Cxs also had differential effects on both islet size and the total insulin content of pancreas, which are two widely accepted indicators of beta-cell mass, in the various null and transgenic strains we compared. Thus, the native Cx36 seemed not to affect betacell mass in agreement with its restricted expression in only poorly proliferating pancreatic beta-cells, adrenal medulla cells, and most neurons (26) . In contrast, the much more widespread Cx32 and Cx43 did so in the presence of native levels of Cx36. However, it is most unlikely that the beta-cell changes were because of the persistent expression of the latter Cx, given that Cx36 does not form heterotypic channels with other Cx species (28,38). Because to ectopically express Cxs in beta-cells, we used the hGH gene as a source of stabilizing polyadenylation sequences, and because GH has a potent in vitro mitogenic effect on beta-cells (41), we checked whether this hormone alone could account for the beta-cell changes we detected in RIP-Cx32 and Cx43 mice. We found that the sole expression of hGH in beta-cells did not increase insulin content, even though it enlarged the size of individual pancreatic islets. We further observed that hGH was expressed in RIP-Cx32 but not RIP-Cx43 mice. Thus, in the former animal strain, the effects of Cx32 may have been synergized by those of hGH. This hormone is known to exert its effects via the JAK-STAT signaling pathway, generating transcription factors that control the expression of multiple target genes (19) . However, this potential synergy cannot account for the changes we observed in the RIP-Cx43 mice, given that these animals did not express hGH. Thus, Cx43 had a remarkable effect on both islet size (in both heterozygous and homozygous mice) and insulin content (only in the latter animals). The underlying mechanism, which could involve increased beta-cell coupling, interactions between Cxs with either membrane or cytosolic proteins (39, 42) , possibly resulting in altered expression of specific genes (39) involved in beta-cell differentiation and/or proliferation, remains to be investigated. Strikingly, the actively proliferating embryonic stem cells that may provide a source for the generation of secretory competent and nonproliferating insulin-producing cells useful in a cell replacement therapy of diabetes express Cx43 but no Cx36 (43) (44) (45) .
The mass of the insulin-producing beta-cells is the balanced result of several factors including changes in beta-cell size, proliferation, life time and cell death, and possibly other mechanisms such as islet cell transdifferentiation and islet neogenesis (8, 24) . The relative impact of each of these mechanisms may vary under different physiological and pathophysiological conditions (8, 24) . The new animal models we report here offer unique tools to further investigate these events and the underlying molecular mechanisms. Parallel studies have revealed that the three Cx species we investigated protect beta-cells in vivo and in vitro against drugs and cytokines that induce beta-cell apoptosis and necrosis, preventing the resulting hyperglycemia (46) . Whether the Cxs are also central to the regulation of beta-cell life in the normoglycemic animals that we have screened here remains to be determined and will be the subject of further studies. Under physiological conditions, beta-cell proliferation and apoptosis is an infrequent event, and islet neogenesis and islet transdifferentiation are still questioned phenomena (8, 24) . Thus, such studies will require long periods of analysis of large numbers of animals.
At any rate, our findings open the possibility that an in vivo modulation of the beta-cell mass is possible by modifying the expression of specific Cxs. Cx36 could do so by reducing the constitutive beta-cell death and improving beta-cell function (26, 46) , Cx32 and Cx43 by increasing beta-cell formation, as indicated by this study. The sequential, regulated expression of these proteins is a novel and attractive strategy to improve the outcome of islet and beta-cell transplantation procedures, which are presently limited by significant losses of the transplanted islets before grafting (47, 48) .
